Alzheimer's disease begins long before any symptoms become apparent. This stage is called preclinical Alzheimer's disease. It's usually identified only in research settings. You and those around you won't notice symptoms during this stage.
This stage of Alzheimer's can last for years, possibly even decades. Although you won't notice any changes, new imaging technologies of the brain can identify amyloid plaques and neurofibrillary tangles. The tangles develop when tau proteins change shape and organize into structures. These are hallmarks of Alzheimer's disease.
The ability to identify these early changes is especially important for clinical trials. Ongoing trials are looking at whether treating people with preclinical Alzheimer's may delay or slow the onset of symptoms. The imaging technologies also are important as new treatments are developed for Alzheimer's disease.
Additional biomarkers have been identified for Alzheimer's disease. These are found in blood samples and can indicate an increased risk of disease. These biomarkers can be used to support the diagnosis of Alzheimer's disease, typically after symptoms appear.
Genetic tests also can tell you if you have a higher risk of Alzheimer's disease, particularly early-onset Alzheimer's disease. These tests aren't recommended for everyone. You and your health care provider can discuss whether genetic testing might be helpful for you.
Newer imaging techniques, biomarkers and genetic tests will become more important as new treatments for Alzheimer's disease are developed.